Enveric Biosciences (ENVB) Stock Analysis

What Enveric Biosciences does

Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.

Key metrics

ETFs linked to ENVB

Broad-market and Healthcare sector ETFs an investor holding Enveric Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ENVB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Enveric Biosciences?

Enveric Biosciences trades under the ticker ENVB on NASDAQ.

Which exchange is ENVB listed on?

ENVB is listed on NASDAQ.

What sector does Enveric Biosciences operate in?

Enveric Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ENVB in a portfolio?

PortView shows ENVB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.